Systematic review / meta-analysis / 2015
Chondroitin alone or with glucosamine provided small to moderate pain improvements compared to placebo in osteoarthritis trials of mostly low quality.
A systematic review analyzed 43 RCTs assessing chondroitin for osteoarthritis. In studies under 6 months, chondroitin yielded significantly lower pain scores (0-100) than placebo (absolute risk difference 10% lower, 95% CI 15% to 6% lower; NNT = 5; n = 8 trials), though trial heterogeneity was high (I² = 70%). For studies over 6 months, the absolute risk difference for pain was 9% lower (95% CI 18% lower to 0%; n = 6 trials). Chondroitin also reduced joint space width loss (relative risk difference 4.7% less, 95% CI 1.6% to 7.8% less) and showed lower odds of serious adverse events compared with placebo (Peto OR 0.40, 95% CI 0.19 to 0.82). However, benefits became uncertain when restricted to studies with appropriate allocation concealment, large sample sizes (>200), or those without pharmaceutical funding.
- Study type
- Systematic review and meta-analysis of RCTs
- Who was studied
- 9,110 adult participants with osteoarthritis (4,962 chondroitin, 4,148 control)
- What was measured
- Pain scores, WOMAC MCII pain, Lequesne's index, joint space width, adverse events
THE PAPER
Chondroitin for osteoarthritis.
Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Cochrane Database Syst Rev, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.